[Skip to Navigation]
October 2015

Memantine-Associated Corneal Endothelial Dysfunction

Author Affiliations
  • 1Price Vision Group, Indianapolis, Indiana
  • 2Cornea Research Foundation of America, Indianapolis, Indiana
JAMA Ophthalmol. 2015;133(10):1218-1220. doi:10.1001/jamaophthalmol.2015.2476

Alzheimer disease (AD) is the most common type of dementia and a growing public health concern. Its estimated prevalence in the United States is 5.2 million cases and is projected to exceed 13 million cases by 2050.1 With no cure available, therapy is palliative via modulation of acetylcholine and glutamate. Current treatment patterns favor cholinesterase inhibitors and N-methyl-d-aspartate (NMDA) receptor antagonists, respectively.2